Quality deviation prompts Telsartan H recall in Uzbekistan

According to the Center for Pharmaceutical Product Safety, quality control and stability tests conducted by the manufacturer found that batch C2501976 of Telsartan H 80 mg/12.5 mg deviated from established standards in terms of the amount of the active ingredient – hydrochlorothiazide. This issue was classified as a nonconformity with the product’s quality specifications.

At the same time, no such discrepancy in the amount of the active ingredient was identified in batch C2501977 that was placed on the market in Uzbekistan. However, because this batch was produced using the same active ingredient manufacturing lot as the nonconforming batch, it is also being recalled from the market as a preventive measure to ensure the safety of medicinal product circulation and to avert potential risks.

In this regard, citizens who purchased Telsartan H 80 mg/12.5 mg from the specified batches are advised not to use the medication, to discontinue its use if they have already started taking it, and, if necessary, to consult their treating physician to select an alternative treatment option.

Earlier, on January 6, it was reported that Nestlé Food LLC JV had begun a voluntary recall of certain limited batches of infant formula in Uzbekistan. Nestlé identified a potential risk related to the possible presence of the cereulide toxin in raw materials (arachidonic acid) obtained from an external supplier. As a result, the company decided to carry out a voluntary recall of certain batches globally.